2022
DOI: 10.1007/s00520-022-06928-4
|View full text |Cite
|
Sign up to set email alerts
|

Use of complementary and integrative health in cancer pain management among patients undergoing cancer treatments: a qualitative descriptive study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2
1

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 31 publications
0
3
0
Order By: Relevance
“…47 Similar qualitative descriptive designs have been used in the populations of cancer and palliative care. 51,52 This research was initially planned before the Covid-19 pandemic. The design was subsequently modi ed prior to data collection in line with public health guidelines.…”
Section: Designmentioning
confidence: 99%
“…47 Similar qualitative descriptive designs have been used in the populations of cancer and palliative care. 51,52 This research was initially planned before the Covid-19 pandemic. The design was subsequently modi ed prior to data collection in line with public health guidelines.…”
Section: Designmentioning
confidence: 99%
“…It is critical to emphasize the importance of opioid use in cancer pain guidelines in conjunction with nonpharmacological pain interventions. Unfortunately, barriers exist to complementary, alternative, and other nonpharmacological pain interventions, such as high cost, poor insurance coverage, lack of knowledge about therapies, and insufficient empirical evidence to support the efficacy of some therapies 22,23 . However, cancer pain treatment recommendations call for a combination of long-acting (scheduled) and short-acting (as needed) opioid formulations to provide continuous analgesia and breakthrough pain control 19–21 …”
mentioning
confidence: 99%
“…Unfortunately, barriers exist to complementary, alternative, and other nonpharmacological pain interventions, such as high cost, poor insurance coverage, lack of knowledge about therapies, and insufficient empirical evidence to support the efficacy of some therapies. 22,23 However, cancer pain treatment recommendations call for a combination of long-acting (scheduled) and short-acting (as needed) opioid formulations to provide continuous analgesia and breakthrough pain control. [19][20][21] Although cancer pain is a commonly studied phenomenon, individuals from minoritized racial, ethnic, and cultural backgrounds are historically underrepresented in this literature.…”
mentioning
confidence: 99%